Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Initiates Gardasil Detailing; Campaign To Focus On Cancer Prevention

Executive Summary

Merck has begun detailing its pending human papilloma virus vaccine Gardasil to non-routine vaccinators, the company reported Dec. 15 during an annual business review in Whitehouse Station, N.J
Advertisement

Related Content

Gardasil Clears FDA, But Dosing May Pose Administrative Challenges
Gardasil Clears FDA, But Dosing May Pose Administrative Challenges
Merck Seeks Early Gardasil Male Recommendation, But FDA, CDC Are Wary
Merck Seeks Early Gardasil Male Recommendation, But FDA, CDC Are Wary
Gardasil Goes To FDA; Merck Hopes For Mid-Year Approval Of HPV Vaccine
Gardasil Goes To FDA; Merck Hopes For Mid-Year Approval Of HPV Vaccine
GSK’s Six Launches, Six Filings Slated For ’06: Sign Of R&D Strategy Payoff?
Advertisement
UsernamePublicRestriction

Register

PS046713

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel